Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen

Background: Nusinersen is an antisense-oligonucleotide (ASO) approved for treatment of 5q-spinal muscular atrophy (SMA). Since the drug cannot cross the blood-brain barrier (BBB), it must be administered into the cerebrospinal fluid (CSF) space repeatedly by lumbar puncture. However, little is known...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Neurol
Main Authors: Wurster, Claudia D., Koch, Jan C., Cordts, Isabell, Dreyhaupt, Jens, Otto, Markus, Uzelac, Zeljko, Witzel, Simon, Winter, Benedikt, Kocak, Tugrul, Schocke, Michael, Weydt, Patrick, Wollinsky, Kurt, Ludolph, Albert C., Deschauer, Marcus, Lingor, Paul, Tumani, Hayrettin, Hermann, Andreas, Günther, René
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854024/
https://ncbi.nlm.nih.gov/pubmed/31787927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.01179
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados